Abstract:BACKGROUND: The RAS/RAF/MEK/ERK and PI3K/AKT/mTOR signaling pathways all belong to mitogen-activated protein kinase (MAPK) signaling pathways, Mutations in any one of the upstream genes (such as the RAS gene or the BRAF gene) may be transmitted to the protein through transcription or translation, resulting in abnormal activation of the signaling pathway. This study investigated the relationship between the KRAS gene mutation and the clinicopathological features and prognosis of colorectal cancer (CRC), and the effect of KRAS mutations on its associated proteins in CRC, with an aim to clarify the cause of tumor progression and drug resistance caused by mutation of the KRAS gene.AIM: To investigate the KRAS gene and RAS pathway signaling molecules in CRC and to analyze their relationship with clinicopathological features and prognosis.METHODS: Colorectal cancer tissue specimens from 196 patients were analyzed for KRAS mutations using quantitative polymerase chain reaction and for KRAS, BRAF, MEK, and ERK protein expression levels using immunohistochemistry of tumor microarrays. To analyze differences of RAS pathway signaling molecule expression levels in different KRAS gene status, the relationships between these parameters and clinicopathological features, 4-year progression-free survival, and overall survival were analyzed by independent sample t test, Kaplan-Meier plots, and the log-rank test. Predictors of overall and disease-free survival were assessed using a Cox proportional hazards model.RESULTS: Of the 196 patients, 62 (32%) carried mutations in codon 12 (53/62) or codon 13 (9/62) in exon 2 of the KRAS gene. KRAS, BRAF, ERK, and MEK protein expression was detected in 71.4%, 78.8%, 64.3%, and 50.8% of CRC tissues, respectively. There were no significant differences between KRAS mutation status and KRAS, BRAF, MEK, or ERK protein levels. Positive expression of KRAS and ERK was associated with poor tumor differentiation, and KRAS expression was also associated with age < 56 years. MEK expression was significantly associated with distant metastasis (P < 0.05). The 4-year progression-free survival rate, but not overall survival rate, was significantly higher in patients with KRAS-negative tumors than in those with KRAS-positive tumors (P < 0.05), whereas BRAF, MEK, and ERK expression was unrelated to survival. Multivariate analysis showed that only the expression of KRAS protein was a risk factor for tumor recurrence (P < 0.05). No other clinicopathological factors correlated with KRAS, BRAF, MEK, or ERK expression.CONCLUSION: KRAS gene mutations do not affect downstream protein expression in CRC. KRAS protein is associated with poor tumor differentiation, older age, and a risk of tumor recurrence.

Effectors of epidermal growth factor receptor pathway: the genetic profiling ofKRAS, BRAF, PIK3CA, NRAS mutations in colorectal cancer characteristics and personalized medicine.

KRAS, BRAF and PIK3CA Mutations and the Loss of PTEN Expression in Chinese Patients with Colorectal Cancer.

Mutation profiling in chinese patients with metastatic colorectal cancer and its correlation with clinicopathological features and anti-EGFR treatment response.

Gene Mutation Profiling in Chinese Colorectal Cancer Patients and Its Association with Clinicopathological Characteristics and Prognosis

Mutation Status and Immunohistochemical Correlation of KRAS, NRAS, and BRAF in 260 Chinese Colorectal and Gastric Cancers

Prognostic Impact of Mutation Profiling in Patients with Stage II and III Colon Cancer

Correlation Between Clinicopathological Features and KRAS, NRAS, and BRAF Mutation Status in Chinese Colorectal Cancer Patients

Relationships among KRAS mutation status, expression of RAS pathway signaling molecules, and clinicopathological features and prognosis of patients with colorectal cancer

A Study on the Relationship Between KRAS, NRAS, BRAF and PIK3CA Gene Mutations and Clinicopathological Features in Patients with Colorectal Cancer

Mutations of KRAS and BRAF in Chinese Patients with Colorectal Carcinoma : Analyses of 966 Cases

BRAF V600E Mutation and KRAS Codon 13 Mutations Predict Poor Survival in Chinese Colorectal Cancer Patients

Somatic mutation profiling and HER2 status in KRAS-positive Chinese colorectal cancer patients

Clinicopathologic Features and Prognostic Value of KRAS, NRAS and BRAF Mutations and DNA Mismatch Repair Status: A Single‐center Retrospective Study of 1,834 Chinese Patients with Stage I–IV Colorectal Cancer

Molecular pathological epidemiology of colorectal cancer in Chinese patients with KRAS and BRAF mutations

Clinical Characteristics and Prognostic Value of the KRAS Mutation in Chinese Colorectal Cancer Patients

Promising Biomarkers for Predicting the Outcomes of Patients Withkraswild-Type Metastatic Colorectal Cancer Treated with Anti-Epidermal Growth Factor Receptor Monoclonal Antibodies: A Systematic Review with Meta-Analysis

[KRAS and BRAF Gene Mutations in Correlation with Clinicopathologic Features of Colorectal Carcinoma in Chinese].

Retrospective analysis of KRAS, NRAS and BRAF gene mutations and clinicopathological features in patients with colorectal cancer

Epidemiological and clinicopathological features of KRAS, NRAS, BRAF mutations and MSI in Chinese patients with stage I–III colorectal cancer

Mutations in Epidermal Growth Factor Receptor and K-ras in Chinese Patients with Colorectal Cancer

NGS-based Oncogenic Mutations Analysis in Advanced Colorectal Cancer Patients Improves Targeted Therapy Prediction.